X0508 4 2025-11-05 0 0001974640 Apogee Therapeutics, Inc. APGE 0001983476 Dambkowski Carl C/O APOGEE THERAPEUTICS, INC. 221 CRESCENT ST., BLDG. 17, STE. 102B WALTHAM MA 02453 0 1 0 0 Chief Medical Officer 1 Common Stock 2025-11-05 4 M 0 8060 22.86 A 292793 D Common Stock 2025-11-05 4 S 0 2300 53.62 D 290493 D Common Stock 2025-11-05 4 S 0 2200 54.83 D 288293 D Common Stock 2025-11-05 4 S 0 5607 55.58 D 282686 D Common Stock 2025-11-05 4 S 0 678 56.51 D 282008 D Stock Option (Right to Buy) 22.86 2025-11-05 4 M 0 8060 0.00 D 2033-12-18 Common Stock 8060 153565 D This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.16 to $53.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.24 to $55.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.25 to $56.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.31 to $56.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer. /s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski 2025-11-07